electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
13 Março 2023 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, announced today that data from a
sham controlled study on the ability of nVNS to Accelerate Second
Language Learning, conducted at the Defense Language Institute in
Monterey, California, will be presented at the 2023 American
Academy of Neurology Annual Scientific Meeting on April 23, 2023 in
Boston, Massachusetts.
Poster
Presentation Details: |
Title: |
Transcutaneous
Cervical Vagus Nerve Stimulation Enhances Second Language
Vocabulary Acquisition While Simultaneously Mitigating Fatigue and
Promoting Focus |
Date: |
Sunday, April 23,
2023 |
Time: |
11:45 a.m. – 12:45
p.m. ET |
Presenter: |
Toshiya Miyatsu,
Ph.D. |
Details: |
Poster Session 2;
P2.12-002 |
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans (including with respect to ongoing
studies); its pipeline or potential markets for its technologies;
the timing, outcome and impact of regulatory, clinical and
commercial developments; the issuance of U.S. and international
patents providing expanded IP coverage; the possibility of future
business models and revenue streams from the company’s potential
use of nVNS for the enhancement of second learning vocabulary
acquisition, the potential of nVNS generally and gammaCore in
particular and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "believes," "intends," other words of similar
meaning, derivations of such words and the use of future dates.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize gammaCore™, the potential impact and effects of
COVID-19 on the business of electroCore, electroCore’s results of
operations and financial performance, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024